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ABSTRACT
This editorial discusses a novel basal insulin
analog, insulin degludec. It describes the
limitations of existing basal insulins, and
builds the case for a better analog. The
editorial discusses the evidence to support the
efficacy, safety, tolerability, and flexibility of
degludec, and assesses its utility as part
of a person-centered approach to diabetes
management.
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INTRODUCTION
Major advances and developments have taken
place in the field of insulin, since its discovery
nearly a century ago. The engineering of insulin
analogs is but one step in this journey of
innovation. Insulin analogs are molecules
which have been created by modifying the
structure of insulin to achieve desired
pharmacokinetic properties. Drugs such as
insulin aspart, glulisine and lispro act as rapid-
acting insulins, while insulin detemir and
glargine work as long-acting basal analogs.
Premixed analogs—biphasic aspart, biphasic
lispro—are also used in clinical practice [1].
CURRENTLY AVAILABLE BASAL
INSULINS
In spite of the various improvements in insulin
pharmaco-therapeutics over the past decades,
there still exist limitations in the existing basal
insulin analogs. These limitations translate to
shortcomings in our current therapeutic
regimes, and impact our ability to achieve
optimal glycemic goals without causing
hypoglycemia.
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Both insulin glargine and insulin detemir
exhibit considerable inter-individual and intra-
individual variabilities. Though this variability
is less for detemir, it is nonetheless clinically
significant [2]. While glargine has duration of
action of up to 24 h, the action of detemir lasts
18–23 h. The duration of action of detemir is
dose-dependent, and both insulins may be
required in a twice-daily regime [3]. Glargine
has an acidic pH, which may be associated
with injection site reactions [1]. If
inadvertently injected intramuscularly,
glargine exhibits the kinetics of rapid-acting
insulin [4]. Neither glargine nor detemir can be




Keeping these issues in mind, the need for a
new basal insulin analog is clear. To be truly
useful, a novel basal insulin must have a long
duration of action, of over 24 h, exhibit
minimal variability, maintain sustained serum
concentrations without any peaks or troughs,
and ensure safety and tolerability [5]. The drug
must be linked with a low risk of hypoglycemia,
especially nocturnal and severe hypoglycemic
episodes. It is noteworthy to mention here that
in the recently reported DAWN2 study, over
half of all people with diabetes, and two-thirds
of family members reported worrying about
hypo [6, 7]. Ideally, the molecule should
provide flexibility of use, without any need for
administration at a constant time of day or with
a specified injection–meal or injection–bed time
gap. Its’ use should require minimal self
monitoring, and be linked with a low index of
intrusion. Availability in patient-friendly
delivery devices and a positive impact on
quality of life will be added advantages. These
qualities will ensure ‘patient-centered care’,
in concordance with current diabetes
management guidelines [1].
DEGLUDEC: PHARMACOLOGY
Insulin degludec is novel ultralong-acting
insulin, recently approved for use in various
countries, including the European Union,
Japan, Mexico and India.
A 50-amino acid structure, it does not have
the threonine present at B30 position in human
insulin. Instead, a glutamic acid spacer links a
16-carbon fatty di-acid chain to the B29 amino
acid residue. This change in structure allows
degludec to exist in a stable di-hexameric
structure in the presence of phenol, in
injection solution. This is in contrast to the
hexameric state of human insulin. Upon
subcutaneous injection, phenol diffuses away,
to allow the degludec di-hexamers to have free
ends and with the help of zinc and fatty acid
side chain to link up and form a soluble multi-
hexameric chain. Zinc, a part of the insulin
molecule, diffuses slowly from the terminal
ends of this chain, allowing slow and stable
absorption of insulin. This provides a long-
acting, consistent delivery of drug, which is not
dependent on blood perfusion of the injection
site [8]. Though degludec binds reversibly to
albumin, this does not contribute much to its
prolonged action.
Degludec links to human insulin receptors
(hIR) and to extremely low for insulin-like
growth factor-1 (IGF-1) (lesser than human
insulin). While it has similar affinity for both
isoforms of hIR (hIR-A and hIR-B), its affinity
for IGF-1 receptor is much lower. Degludec has
metabolic effects which are similar to that of
human insulin, but mitogenic effects of a
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lower potency (4–14%). Hence, it is very safe
for use, without increased risk of mitogenicity
[9].
Degludec enjoys a pharmacokinetic profile
which is unique among all insulin and insulin
analogs: a long half-life of 25.4 h ensures that
the duration of insulin degludec was beyond
42 h as detected by euglycaemic clamp studies
[10]. As it has a stable pharmacokinetic profile,
its concentration does not vary, once it reaches
a steady-state concentration. This happens
within 3 days of injection. This is unique and
gives flat peakless profile of insulin degludec
compared to available basal insulin which has
a peak and a trough. There is minimal
variability in insulin concentration and its
insulin lowering action for insulin degludec
after each injection. This is in contrast to
glargine which has higher concentration in the
first 12 h after dosing, as compared to the
second 12 h post-dosing period [11]. This
difference is explained by the relatively lesser
amount of glargine present in the
subcutaneous space after its half-life of 12.5 h
is completed. The variability of glargine is
found to be 4 times higher as compared to
insulin degludec, when analyzed by
euglycaemic clamp studies. Analysis of the
24 h pharmacodynamic profile reveals that
insulin degludec is equally distributed along
the day with approximately 25% in each
quarter of the day, i.e., every 6 h.
Pharmacokinetics of insulin degludec has also
been assessed to be similar in patients with
renal and hepatic impairment, irrespective of
degree of impairment.
DEGLUDEC: CLINICAL TRIALS
The advantages of degludec have been borne
out in clinical studies. The BEGIN studies have
reported on the utility of insulin degludec as a
basal insulin therapy, and as part of a basal-
bolus regime, in both type 1 and type 2
diabetes. The BOOST studies evaluate a
combination of degludec and aspart insulin in
the same manner.
The efficacy of degludec has been proven
in these treat-to-target trials. Treat-to-target
trials are designed as required by the
regulatory bodies like the US Food and Drug
Administration (FDA), where insulins are
analyzed for non-inferiority of efficacy, while
safety analysis is done to establish risk benefit
of the newer insulin in comparison to the
existing molecule. Degludec stands out is in
its ability to achieve glycemic goal with a
significantly lower risk of hypoglycemia.
Degludec has been analyzed in phase 3a
clinical trials wherein both safety and
efficacy have been analyzed in comparison
with various comparators. Seven out of nine
phase 3a trials are in comparison with
glargine and one with detemir and one with
dipeptidyl peptidase-4 (DPP4) inhibitor. As the
design was treat to target, all these trials had
similar fasting glucose target of 71–89 mg/dL,
and all trials achieved successful glycated
hemoglobin (HbA1c) reduction with both
degludec and comparator. With the same
targets now achieved, safety analysis showed
benefit of insulin degludec consistently
throughout clinical trial program.
Degludec was associated with lower
incidence of confirmed hypoglycaemia as well
as significant reduction in nocturnal
hypoglycaemia. As part of a basal-bolus regime
with insulin aspart, the rate of nocturnal
hypoglycemia was 25% lower with degludec
than glargine, in a phase 2 proof of concept
study in type 1 diabetes, as well as in a type 2
diabetes study [12, 13]. When used as basal
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therapy with oral anti-diabetic drugs in type 2
diabetes, a 36% lower rate of nocturnal
hypoglycemia and 86% lower rate of severe
hypoglycemia were observed [14].
Degludec, however, was associated with a
numerically higher incidence of hypoglycemia
in clinical trials on patients with type 1
diabetes, especially those from USA, as
compared to those from Europe [15]. Among
subjects with type 1 diabetes, 63.8% were
randomized in the USA. Among subjects with
type 2 diabetes, 32.7% were randomized in the
USA. Subjects randomized outside of the USA
experienced a non-statistically significant
increase in the rate of confirmed
hypoglycemia associated with degludec in type
1 diabetes, RR 1.28, 95% CI (0.96, 1.71), and a
statistically significant decrease in confirmed
hypoglycemia in type 2 diabetes, RR 0.79, 95%
CI (0.69, 0.90). However, among subjects
randomized in the USA, there was no observed
difference in the rate of confirmed
hypoglycemia between degludec and glargine
in either type of diabetes: T1DM RR 0.99, 95%
CI (0.81, 1.20), and T2DM RR 0.97, 95% CI
(0.81, 1.15).
The prolonged duration of action of
degludec allows for flexibility in its time of
administration. Studies performed in both type
1 and type 2 diabetes [16, 17] have assessed that
fixed time and flexible degludec regimes offer
similar efficacy and safety. A forced flexible
dosage schedule, involving degludec injections
at intervals of 8 h, followed by 40 h, and again
by 8 h, was successful in achieving glycemic
target without increasing the risk of
hypoglycemia. This could be an advantage for
patients wherein they can take insulin degludec
at any time depending on their daily schedule
without affecting efficacy or possess safety
concern.
PRACTICAL USAGE
Apart from consistency, efficacy, and safety
(low risk of hypoglycemia), degludec offers the
advantage of flexibility. This is not to suggest
that all people with diabetes must necessarily
be put on flexible or staggered regimes of
degludec. Rather, it implies that both health
care professionals and people with diabetes
need not be rigid about the timing of
injections. This should make insulin therapy,
much easier, less intrusive, less demanding,
and more acceptable. Endocrinologists may
draw a parallel with the pharmacokinetic
profile of other hormones. Thyroxine, though
administered once daily, can be given as a
weekly dose, in view of its long half-life [18].
Similarly, if one dose of oral contraceptive is
missed, the recommendation is to take the pill
the following day, without fear of loss of
efficacy or difficulty in tolerability [19].
Human chorionic gonadotropin is also
injected at 48 or 72 h intervals without much
emphasis being laid on exact 48 h spacing [20].
Degludec can be used as both basal and
basal-bolus therapy, in type 1 and type 2
diabetes impairment. Currently, its use has not
been reported in pregnancy or in children
below age of 18. Long-term studies are
available in degludec for up to 2 years, and
further trials are underway to collect data on
cardiovascular safety of this molecule. US FDA
has requested additional clinical data from a
dedicated cardiovascular outcomes trial before
the review of the New Drug Applications can be
completed as a number of additional analyses,
some of which showed an unfavorable
numerical imbalance between insulin degludec
and degludec/aspart premixed combination,
and comparators, though pre-specified major
adverse cardiac events (MACE) analysis
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showed no increased cardiovascular risk versus
comparator with a point estimate of 1.097
[0.681;1.768] [21].
POSOLOGY
The dosage of degludec is decided as for other
basal insulins (Table 1). In a treatment-naı¨ve
person, a starting dose of 0.1–0.2 units/kg/day,
at anytime of the day, is a useful starting dose
[22]. Physicians may begin therapy with a
standard dose of 10 U/day, and uptitrate
gradually, based on fasting glucose levels, at
weekly or biweekly intervals. Any dose of
degludec will take 2–3 days to reach a steady-
state concentration, and hence daily dose
titration is not recommended. In a basal-bolus
regime based on analogs, including degludec,
the ratio of degludec to bolus analog will be
roughly 50:50. In persons already on another
basal insulin, a 1:1 ratio is followed while
shifting patients from one basal insulin to
another, i.e., the dose is not changed.
However, if a twice-daily basal regime is
converted to once-daily analog, either a 1:1
switch or a slight dose reduction may be
considered [22]. Some studies have shown
about 10% reduction in dose requirement with
degludec. Degludec monotherapy will not be a
good option for patients uncontrolled on
premixed insulin or on basal-bolus regime: it
must be prescribed in conjunction with rapid-
acting insulin in such situations.
CONCLUSION
As degludec becomes more and more widely
used, it should set off a virtuous cycle leading to
good glycemic control: prescription of degludec
helps in achievement of glycemic targets
without hypoglycemia, without enforcing a
tight prescription schedule, leading to
improved patient satisfaction, further
enhancing acceptance of insulin therapy.
Hopefully, this novel ultralong-acting basal
insulin should be the torchbearer of concerted
efforts to achieve optimal glycemic control in a
patient-friendly, patient-centered manner.
Table 1 Initiating degludec therapy: practical guidance
Clinical scenario Initial dose Titration
Insulin naive 0.1–0.2 U/kg/day, or 10 U/day;
once daily
Biweekly or weekly, based on fasting
glucose
Already on other basal insulin,
once daily
1:1 switch; once daily Biweekly
Already on other basal insulin,
twice daily
1:1 switch; once daily As above
On premixed insulin Degludec ? aspart premixed combination;
1:1 switch for basal component OR
Degludec ? bolus therapy
Biweekly or weekly, based on fasting and
postprandial glucose
On basal-bolus regime, with
other basal insulin
1:1 switch for basal dose; once daily As above
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